Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853 |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Luciferase reporter assay, Western blot, RIP |
| Sample | lung cancer tissues, cell lines (A549, H1299, H469, SPC-A1 and A549/DDP, NHBE) |
| Expression Pattern | up-regulated |
| Function Description | Lung cancer patients with high MALAT1 levels were associated with cisplatin resistance and low overall survival.MALAT1 knockdown in lung cancer cells resulted in miR-101-3p upregulation and increased cisplatin sensitivity.miR-101-3p decreased myeloid cell leukemia 1(MCL1) expression by binding to the 3'-untranslated region (3'-UTR) of its mRNA. MALAT1/miR-101-3p/MCL1 signaling underlies cisplatin resistance in lung cancer. |
| Pubmed ID | 29484127 |
| Year | 2017 |
| Title | MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |